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ABSTRACT 
Hyperammonemia leads to neurotoxic levels of brain ammonia and is a major factor 
involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia‐lowering 
treatments primarily involve two strategies: inhibiting ammonia production and/or 
increasing ammonia removal. Targeting the gut has been the primary focus for many 
years, with the goal of inhibiting the generation of ammonia. However, in the context of 
liver failure, extrahepatic organs containing ammonia metabolic pathways have become 
new potential ammonia‐lowering targets. Skeletal muscle has the capacity to remove 
ammonia by producing glutamine through the enzyme glutamine synthetase (amidation 
of glutamate) and, given its large mass, has the potential to be an important ammonia‐
removing organ. On the other hand, glutamine can be deaminated to glutamate by 
phosphate‐activated glutaminase, thus releasing ammonia (ammonia rebound). Therefore, 
new treatment strategies are being focused on stimulating the removal of both ammonia 
and glutamine. 
Hepatic encephalopathy (HE) is a common, debilitating, and clinically challenging 
neuropsychiatric complication of both acute liver failure and chronic liver disease. 
Characterized by a constellation of symptoms, including a spectrum of cognitive, 
psychiatric, and motor disturbances, HE can progressively lead to coma and death. In 
1998, the working party at the 11th World Congress of Gastroenterology classified HE 
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into three types, based on the nature of hepatic dysfunction. Type A HE is associated 
with acute liver failure; type B occurs with portal‐systemic shunting (bypass) without 
intrinsic liver disease; and type C develops in patients with cirrhosis (Figure 1). This 
review focuses on the role of ammonia in the pathogenesis of type C HE and describes 
various ammonia‐lowering therapeutic strategies.  
 
Figure 1 Classification and types of hepatic encephalopathy. Based on the underlying 
cause, hepatic encephalopathy (HE) is divided into three forms: (1) type A, associated 
with acute liver failure; (2) type B, arising because of portal‐systemic shunting in the 
absence of any intrinsic liver disease; and (3) type C, which develops in patients with 
cirrhosis. Type C HE can be further divided into (a) overt HE (OHE), which is diagnosed 
from obvious clinical signs such as hyperreflexia, rigidity, myoclonus, asterixis, stupor, 
and seizures, and (b) minimal HE, which is described when no overt or obvious 
symptoms of HE are observed and is diagnosed using sensitive neuropsychologic and 
neurophysiologic tests. OHE can then be further subdivided into (i) episodic HE, 
characterized by bouts of clinically overt symptoms developing over a short period of 
time, and (ii) persistent HE, characterized by continuous symptoms of OHE. 
Cirrhosis‐related HE is further classified into two forms: minimal HE (MHE) and overt 
HE (OHE). In MHE, no overt or obvious manifestations of HE are observed; it is 
diagnosed using sensitive neuropsychological and neurophysiological tests.
1
 MHE is 
characterized by decreased attention, poor concentration, impaired memory, sleep 
This is the peer reviewed version of the following article: Rose C F. Ammonia-Lowering Strategies for the Treatment 
of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-09;92(3):321–331, which has been published in final form at 
10.1038/clpt.2012.112. This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Use of Self-Archived Versions. 
 
Rose C F. Ammonia-Lowering Strategies for the Treatment of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-
09;92(3):321–331 
disturbances, reduced speed of information processing, and altered motor abilities. In 
addition, the subclinical cognitive impairment that characterizes MHE increases the risk 
of having a car accident. As such, MHE has a significant impact on patients' health‐
related quality of life and their ability to carry out day‐to‐day functions.1 As many as 80% 
(20–80%, depending on the severity of the disease) of patients with chronic liver disease 




OHE may involve several clinical signs, including hyperreflexia, rigidity, myoclonus, 
asterixis, stupor, and seizures; the West Haven Criteria are routinely used to grade the 
severity of manifestations. In addition, based on the duration and characteristics of 
neurologic dysfunction, OHE can manifest as either episodic or persistent. HE is said to 
be episodic when bouts of clinically overt symptoms develop over a short period of time, 
whereas persistent HE is defined as the continuous presence of symptoms (Figure 1). 
Patients with persistent HE are usually unresponsive to treatment. In patients with end‐
stage liver disease, there is a 20% annual risk of developing an episode of OHE, and the 
prevalence of OHE among these patients is 30–45%.
3
 The clinical prognosis is poor after 
OHE has developed, with 1‐year survival estimated at 42% and 3‐year survival at 23%.2 
Overall, the burden of HE is immense, considering its wide‐ranging effects on patients, 
their families, and society. The economic drain caused by HE on health‐care systems is 
estimated at more than US$1 billion annually. With the increasing prevalence of hepatitis 




REGULATION OF AMMONIA 
The pathophysiologic basis of HE is multifactorial and complex, and it remains poorly 
understood. However, there is general consensus that ammonia plays a pivotal role in 
HE.
5,6
 Ammonia, a by‐product of nitrogen metabolism, is produced mainly within the gut 
through the deamination of glutamine by glutaminase in the enterocytes of the small 
intestine and colon, as well as through the hydrolysis of urea, catalyzed by urease‐
producing bacteria that exist abundantly in the human gut. Gut‐derived ammonia is 
transported and absorbed across the mucosal epithelium into the hepatic portal 
circulation, from which, in the case of a healthy liver, it is removed primarily through the 
urea cycle. This low‐affinity, high‐capacity ammonia detoxification system is present in 
the periportal hepatocytes located around the portal vein. Glutamine synthetase, another 
important ammonia‐removing pathway located in the liver, catalyzes the amidation of 
glutamate into glutamine, thereby removing an ammonia molecule. This high‐affinity, 
low‐capacity reaction takes place in the perivenous hepatocytes located around the 
hepatic vein and acts as a scavenger for the ammonia that escapes periportal urea 
synthesis. The production of ammonia within the gut and its detoxification by the liver 
are the main pathways through which ammonia homeostasis is maintained in the body. 
However, other organs also contribute to ammonia metabolism. In addition to the liver 
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and intestines, glutamine synthetase is found in the muscles and the brain (particularly in 
the astrocytes) and in phosphate‐activated glutaminase in the kidneys and the brain 
(primarily in the neurons). In the presence of a healthy liver, blood ammonia levels are 
maintained in the low range of 35–60 µmol/l (Figure 2). However, during liver disease, 
given the reduced hepatic capacity for ammonia removal, the extrahepatic interorgan 
ammonia metabolism is altered (including glutamine metabolism),
7
 thus upsetting the 
balance between ammonia‐producing/removing organs and ammonia homeostasis 
(Figure 2). This results in a two‐ to fivefold increase in blood ammonia, leading to an 




Figure 2 Interorgan ammonia (NH3) and glutamine (GLN) trafficking under normal and 
cirrhotic conditions. Many organs are involved in regulating whole‐body ammonia 
homeostasis. (a) The liver is the most important organ in regulating the circulating 
concentration of ammonia to remain in the range 35–60 µmol/l. (b) During liver 
disease, the arterial concentration of ammonia can increase fivefold. This is obviously 
due to lower ammonia detoxification in the liver (reduced urea‐cycle and glutamine 
synthetase (GS) activity). Furthermore, under these conditions, interorgan metabolism is 
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altered. The muscle becomes the major ammonia‐removing organ, through the GS 
mechanism; however, attempts by the muscle to detoxify ammonia by means of forming 
and releasing GLN are negated when GLN is metabolized by phosphate‐activated 
glutaminase (PAG) in both the kidney and the intestine. With a net balance of zero 
ammonia removed, and continuous production of ammonia in the gut (by diet as well as 
PAG/urease activity), hyperammonemia will persist. For a complete review of interorgan 
ammonia metabolism in liver disease, please see ref. 
7
. Red circles: circulating ammonia; 
blue circles: circulating GLN; orange circles: GLN‐derived ammonia. 
PROPERTIES OF AMMONIA 
Ammonia as a gas (NH3) can freely diffuse across all cell membranes, and as an ion 
(NH4
+
) it can be transported across plasma membranes through K
+
 transporters and 
channels because it has properties similar to those of K
+
 (comparable ionic radius and 
diffusion coefficient). The ratio of NH3/NH4
+
 is a function of pH as defined by the 
Henderson‐Hasselbach equation: log10 (NH3/NH4
+
) = pH − pKa, where pKa is dissociation 
constant. With the pKa of ammonia being 9.15 (at 37 ºC and pH 7.4) >98% of ammonia is 
present as NH4
+
. There is increasing evidence to indicate that ammonia can also be 
transported through aquaporin channels, as well as through human nonerythroid Rhesus 
glycoproteins B and C (Figure 3). It has been proposed that an ammonia concentration 
gradient exists between the brain and the blood. However, studies in animals with and 
without liver failure have demonstrated similar concentrations of ammonia in the blood, 
cerebrospinal fluid, and extracellular fluid (sampled using in vivo cerebral 
microdialysis),
8,9
 including a strong correlation between arterial and extracellular cerebral 
ammonia.
10
 It is understood that a difference in pH across plasma membranes, i.e., 
between intracellular and extracellular compartments, will alter the ratio of NH3/NH4
+
 on 
either side of the membrane. A pH gradient between blood and brain will create 
concentration gradients for NH3 and NH4
+
 across the blood–brain barrier. However, 
given that both NH3 and NH4
+
 are capable of crossing biological membranes (NH3 
diffuses faster than NH4
+
 is transported), the concentration levels of ammonia (NH3 + 
NH4
+
) in the blood and in the brain will reach equilibrium and be similar. Nevertheless, it 
has been demonstrated that an increase in blood ammonia leads to an increase in cerebral 
uptake;
11
 but this does not necessarily dictate an accumulation of ammonia in the brain, 
nor does it, therefore, entail a higher concentration in the brain. Given that ammonia 
follows its concentration gradient, and that astrocytes (which outnumber neurons ~1.5:1) 
detoxify ammonia through the synthesis of glutamine by glutamine synthetase, the brain 
becomes a sink for ammonia. Therefore, the concentration of blood ammonia as well as 
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Figure 3 Mechanisms and effects of ammonia uptake into the brain. Ammonia in the 
form of NH3, being a gas, can diffuse across cell membranes, whereas NH4
+
 is 
transported across plasma membranes by K















 symporters, (4) ammonia transporters, and (5) 
aquaporins. An increase in neurotoxic levels of ammonia leads directly to shifts in pH, 
changes in membrane potential and a compromised metabolism, causing deleterious 
effects such as astrocyte swelling, energy impairment, and alterations in 
neurotransmission. 
NEUROTOXICITY OF AMMONIA 
HE is often precipitated by ammoniagenic conditions such as the ingestion of a protein 
load, constipation, or a gastrointestinal bleed, resulting in an elevation of ammonia 
concentration in the brain. HE then triggers a cascade of metabolic events that are 
implicated in its development. The neurotoxicity of ammonia is explained by the direct 





 and NH3) can act as a weak base or as a weak acid and is therefore capable of 
altering the pH of the environment.
13




 have comparable 
properties, an increase in NH4
+
 can lead to a change in resting membrane potential, 
thereby exerting a direct effect on neurotransmission.
5
 Furthermore, ammonia is an 
important metabolic end product as well as an intermediate of many different 
biochemical reactions in the body; therefore, an increase in ammonia will have an impact 
on cellular metabolism and function as well. These direct effects of ammonia, together or 
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independently, can lead to several pathophysiologic mechanisms that affect cellular 
functions, including cellular energy metabolism, neurotransmission, and astrocyte 
swelling
6
 (Figure 3).  
NEUROPATHOLOGY 
The neuropathology of HE in chronic liver disease primarily reveals morphological 
changes in astrocytes, including cell swelling and the development of Alzheimer type II 
astrocytosis. Loss of neuronal cells is rarely observed in liver disease. Astrocyte swelling, 
which is responsible for brain edema, is a common feature found in cirrhotic rats with 
MHE
8,14
 as well as in patients with cirrhosis who develop HE.
15
 When there is an 
increase in ammonia levels in the brain, it is the astrocyte that bears the brunt of 
removing ammonia because these glial cells are the only cells in the brain capable of 
detoxifying ammonia through the synthesis of glutamine by glutamine synthetase. It has 
been postulated that the accumulation of glutamine in astrocytes, subsequent to ammonia 
detoxification, results in an increase in osmotic forces, leading to swelling in HE. 
However, our group and others have demonstrated that glutamine is not the sole factor 
involved in the pathogenesis of astrocyte swelling,
16
 and that the precise 
pathophysiologic mechanisms underlying the development of brain edema in HE remain 
unexplained. More importantly, given that the swelling of astrocytes not only leads to 
brain edema but is also capable of compromising cell function, it remains controversial 
whether brain edema symbolizes a neuropathologic feature of HE, or whether HE is a 
clinical manifestation of brain edema.  
THE ROLE OF AMMONIA IN HE 
Although there is overwhelming evidence of the central role of ammonia in the 
pathogenesis of HE, and data show that 80% of patients with cirrhosis present some 
degree of hyperammonemia,
17
 it is important to note that many studies have reported an 
imperfect correlation between hyperammonemia and the severity of HE in chronic liver 
disease.
18
 This suggests that pathogenic factors besides ammonia are involved in the 
pathogenesis of HE. It has been speculated that oxidative stress and inflammation may 
exacerbate the neuropsychologic effects of hyperammonemia.
8,19,20
 The roles of these 
pathophysiologic factors in the development of HE are not addressed in this review.  
TREATMENTS 
Currently, treatment for HE is based on strategies aimed at reducing the concentration of 
circulating blood ammonia (Figure 4). One obvious strategy is to address the source of 
ammonia production, with the gut being a primary target. Reducing ammonia production 
will minimize its absorption into the systemic circulation and hence the brain's exposure 
to it. However, because interorgan ammonia metabolism is altered during the onset of 
liver disease,
7
 additional organs, such as skeletal muscle, become important players in the 
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metabolism of ammonia. Skeletal muscle, which contains the ammonia‐removing 
enzyme glutamine synthetase, makes up ~40% of total body mass. Therefore, increasing 
the capacity of skeletal muscle to remove ammonia is a potential approach in the 
treatment of HE.  
 
Figure 4 Ammonia‐lowering strategies. 
DECREASING AMMONIA PRODUCTION 
Protein restriction. Protein restriction was once a common therapeutic option for 
cirrhotic patients to prevent a rise in gut‐derived blood ammonia. This approach is no 
longer recommended because it promotes protein degradation, decreases muscle mass, 
and can cause deterioration in the patient's nutritional status.
21
 The available evidence 
does not support protein restriction, and proper nutrition is recognized as being a very 
important element of the management of patients with chronic liver disease. Current 
dietary recommendations are 35–40 kcal/kg/day and 1.2–1.5 g protein/kg/day.
21
 
Malnutrition is a common complication of chronic liver disease and is estimated to affect 
between 25 and 80% of cirrhotic patients. It increases with the severity of the disease and 
is an important prognostic indicator of clinical outcome. The liver plays a critical role in 
maintaining proper nutrition by regulating the traffic of nutrients; during liver disease, 
this metabolic balance becomes deregulated, causing numerous nutritional and metabolic 
complications. Several factors contribute to the development of malnutrition in liver 
disease (for a review, see ref. 
21
), and malnutrition is associated with an increased 
prevalence of HE. In addition, HE is also believed to lead to poor nutritional intake, thus 
creating a vicious circle. Overall, the role of nutrition as a key component in the 
pathogenesis of HE has been undervalued.  
Nonabsorbable disaccharides. To date, nonabsorbable disaccharides, particularly 
lactulose, are the first‐line therapy for patients with end‐stage liver disease and HE. 
Lactulose is a synthetic disaccharide composed of the monosaccharides fructose and 
galactose. It remains undigested until it reaches the colon, where it is metabolized by 
colonic bacteria into acetic acid and lactic acid. These carboxylic acids reduce the 
intraluminal pH and the resulting acidification of the colon suppresses the growth of the 
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intestinal urease bacteria (ammoniagenic bacteria), leaving acid‐resistant, 
nonammoniagenic bacteria. Lactulose also decreases the absorption of ammonia through 
a cathartic effect, clearing the gut of ammonia before it is systemically absorbed, 
resulting in increased fecal nitrogen excretion. Lactulose has also been shown to impede 
the uptake of glutamine by the intestinal wall, thus preventing glutamine from being 
metabolized into ammonia.
22
 As a result, numerous studies have demonstrated that 
lactulose treatment leads to a reduction in blood ammonia levels.
23
 However, in 2004, a 
Cochrane review evaluating 22 clinical trials concluded that there was not enough 
convincing evidence arising from high‐quality randomized trials to suggest that 
nonabsorbable disaccharides should be used to treat HE.
24
 Since then, the results from a 
randomized clinical trial have shown that lactulose is beneficial in treating HE in patients 
with chronic liver disease.
25
 Although lactulose is safe, compliance is often 
underachieved, given the need to titrate the dose in order to reach two or three semi‐soft 
stools per day. In addition, lactulose treatment has been shown to cause abdominal 
cramping, bloating, nausea, vomiting, flatulence, and abdominal distension, the last 
potentially leading to technical difficulties during surgery for liver transplantation. 
Moreover, lactulose treatment affects intestinal absorption, and this may amplify the 




Antibiotics. Orally administered antimicrobial agents targeting the gut have long been 
utilized with the primary aim of inhibiting urease‐containing bacteria in the colon, 
thereby decreasing ammonia production and preventing absorption through the 
gastrointestinal tract. Antibiotics such as neomycin, metronidazole, and vancomycin have 
all been demonstrated to lower blood ammonia in patients with end‐stage liver 
disease.
27,28,29
 Nonetheless, because of the systemic absorption of these antimicrobial 
agents, serious adverse effects have been recorded, and these have limited their 
widespread use. Neomycin, an aminoglycoside antimicrobial, exerts its effect by binding 
to the 30S ribosomal unit and inhibiting protein synthesis. Because neomycin is 
systemically absorbed (~4%), oral treatment potentially causes nephrotoxicity and 
ototoxicity.
30
 Metronidazole, a nitroimidazole antimicrobial that is primarily taken up by 
anaerobes and causes cell toxicity, has been found to be as effective as neomycin.
28
 
However, because of its high systemic absorption, cases of neurotoxicity (peripheral 
neuropathy) have been documented with long‐term use.31 Furthermore, metronidazole is 
eliminated by the liver through hepatic oxidation, which adds to the risk of toxicity in 
patients with chronic liver disease.
32
 Vancomycin, a glycopeptide antimicrobial that 
inhibits cell‐wall synthesis in Gram‐positive bacteria, has been demonstrated to lower 
blood ammonia and attenuate HE in patients with cirrhosis.
29
 On the other hand, 
vancomycin treatment has also been demonstrated to lead to bacterial overgrowth and 
increase the risk of enteric bacterial resistance.
33
 In 2010, results from a randomized, 
double‐blind study led to the approval (in the United States) of the antibiotic rifaximin 
(Salix Pharmaceuticals) as reducing the risk of recurrence of overt HE in patients with 
end‐stage liver disease.34 Rifaximin is a semisynthetic antibiotic that is poorly absorbed 
(<0.4%) because of its pyridoimidazole ring. Rifaximin binds to the β‐subunit of bacterial 
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DNA‐dependent RNA polymerase and prevents the catalysis of polymerization of 
deoxyribonucleotides into a DNA strand, thereby inhibiting bacterial RNA and protein 
synthesis. As a result, rifaximin has a broad spectrum of antibacterial activity, including 
both aerobic and anaerobic and Gram‐positive and Gram‐negative bacteria. Rifaximin 
has proven to be efficient in lowering blood ammonia levels in patients with HE by 
reducing the growth of ammonia‐producing bacteria.35 In contrast to other antibiotics, 
rifaximin is poorly absorbed in healthy individuals; however, its absorption in patients 
with severe liver disease remains to be tested. Rifaximin treatment has resulted in fewer 
adverse effects and a faster and greater decrease in blood ammonia in comparison with 
neomycin.
36
 Furthermore, higher compliance rates have been documented with rifaximin 
as compared with lactulose.
37
 Rifaximin treatment has also been shown to reduce both the 
frequency and duration of hospitalization, thereby lowering hospital‐related costs.4,37 All 
these factors make rifaximin an ideal choice for the treatment of HE, despite a higher per‐
treatment cost.  
Probiotics. Probiotic therapy involves monocultures or mixed cultures of live 
microorganisms, administered orally to improve the properties of the intestinal 
microflora. Studies have shown that probiotics are beneficial in the treatment of HE, 
possibly by modulating intestinal bacteria via the colonization of non‐urease bacteria and 
by lowering blood ammonia concentrations.
38
 Moreover, probiotic supplementation in 
patients with HE has been shown to be very well tolerated, and the compliance rates were 
excellent.
39
 A Cochrane review published in 2011 on the use of probiotics in patients 
with HE concluded that probiotics do reduce the concentration of plasma ammonia, but 
their efficacy in altering clinically relevant outcomes was inconclusive; further 
randomized clinical trials were suggested.
40
 Moreover, some hesitation has been 
expressed with respect to introducing live bacteria into immunocompromised patients. 
An additional concern regarding probiotic treatment is that there are significant variations 
of the live microorganisms and a lack of standardization among probiotics manufacturers. 
VSL #3 (VSL Pharmaceuticals), a combination of probiotics (bifidobacteria, lactobacilli, 
and a mixture of Streptococcus thermophilus strains), was proposed in 2003 as a 
promising probiotic therapy for HE.
41
 However, it has not yet been investigated in 
patients with HE. Efforts to identify the specific bacterial families/strains/species 
associated with urease activity and hyperammonemia may help advance the field of 
probiotic therapy in HE.
42
 
Carbon microspheres. AST‐120 (Ocera Therapeutics) is an oral adsorbent that has been 
shown to be beneficial in patients with chronic kidney disease,
43
 irritable bowel 
syndrome,
44
 and active pouchitis.
45
 AST‐120 consists of engineered activated carbon 
microspheres (0.2–0.4 mm in diameter) with high nonspecific adsorptive surface area 
(>1,600 m
2
/g). These microspheres are not absorbed or degraded in the gastrointestinal 
tract and provide sustained binding surface for low‐molecular‐weight compounds (<10 
kDa) such as those present in the bowel.
45
 AST‐120 has been shown to absorb ammonia 
in vitro and also to reduce hyperammonemia, attenuate brain edema, and attenuate HE in 
cirrhotic rats.
46
 In addition, AST‐120 has the capacity to act as an ammonia sink by 
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drawing ammonia in from the systemic circulation
46
 (Figure 5). This means that AST‐120 
absorbs not only the ammonia produced locally in the gut but also the ammonia produced 
by extraintestinal organs. This property makes AST‐120 attractive as an ammonia‐
lowering treatment for HE. In preliminary studies, patients with low‐grade HE showed 
significant neurocognitive improvements after AST‐120 treatment.47 The efficacy, safety, 
and tolerability of AST‐120 in the treatment of MHE were evaluated in a recent 
multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging clinical trial. 
This study (the ASTUTE trial) was carried out in 150 patients randomized to AST‐120 (6 
and 12 g/day) or placebo for 8 weeks. AST‐120 failed to attenuate MHE after 4 and 8 
weeks of treatment. However, AST‐120 treatment at both doses (6 and 12 g/day) did 
result in a reduction in blood ammonia levels at both 4 and 8 weeks in patients with 
elevated ammonia levels at baseline. Given its high ammonia‐absorbing capacity (300 
µmol/l/g) and the high compliance rate associated with it, AST‐120 thus remains a 
promising treatment for HE. However, a well‐designed clinical trial with a longer 
duration of treatment is needed to prove the efficacy of AST‐120 as a treatment for HE. 
Moreover, evaluations of the recurrence rates of HE, hospital readmissions and costs 
would also be important end points.  
 
Figure 5 AST‐120 as an ammonia sink. With the large capacity of AST‐120 to absorb 
ammonia, it can also draw ammonia from blood circulation. Once absorbed by AST‐120 
in the lumen, ammonia will cross the intestinal wall into the lumen following its 
concentration gradient. 
Sodium benzoate. Sodium benzoate conjugates with the amino acid glycine to form 
hippuric acid, which is excreted by the kidneys. Glycine is metabolized through the 
glycine cleavage system, an enzyme complex that consists of four proteins and generates 
ammonia as an end‐product. Sodium benzoate is administered to prevent glycine 
metabolism and thereby prevent the production of ammonia. Sodium benzoate has been 
widely used in the therapeutic regimen to alleviate hyperammonemia in children born 
with urea cycle disorders.
48
 In the context of liver disease, a randomized, double‐blind 
study demonstrated that sodium benzoate reduces blood ammonia levels and attenuates 
This is the peer reviewed version of the following article: Rose C F. Ammonia-Lowering Strategies for the Treatment 
of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-09;92(3):321–331, which has been published in final form at 
10.1038/clpt.2012.112. This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Use of Self-Archived Versions. 
 
Rose C F. Ammonia-Lowering Strategies for the Treatment of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-
09;92(3):321–331 
the symptoms of HE as effectively as lactulose, in cirrhotic patients.
49
 However, it has 
also been demonstrated that sodium benzoate can inhibit the production of urea, inducing 
hyperammonemia. The conjugation of sodium benzoate with glycine proceeds in two 
steps. First, benzoate and ATP (adenosine triphosphate) react with CoA (coenzyme A) to 
form benzoyl CoA, AMP (adenosine monophosphate), and pyrophosphate. Next, benzoyl 
CoA and glycine react to form hippuric acid and CoA. This second step is dependent on 
the concentration of glycine. Therefore, under conditions of low concentrations of 
glycine, benzoate‐induced utilization of CoA could lead to a decrease in the activation of 
carbamyl phosphate synthetase I, thereby reducing urea cycle activity. This suggests that 
the efficacy of sodium benzoate is dependent on the level of functioning of the urea 
cycle, with a beneficial response occurring when the urea cycle is impaired.
50
 However, 
the effectiveness of using sodium benzoate as an ammonia‐lowering strategy in the 
context of liver disease and residual hepatocyte function remains unclear.  
Sodium phenylacetate/phenylbutyrate. Sodium phenylbutyrate, which is rapidly oxidized 
into phenylacetate, is used to treat hyperammonemia by attenuating hyperglutaminemia 
in children with urea‐cycle enzyme deficiencies.51 Phenylacetate conjugates with 
glutamine in the liver and kidney to form phenylacetylglutamine, which is incapable of 
being metabolized by glutaminase, and therefore glutamine‐stimulated ammoniagenesis 
is prevented. Phenylacetylglutamine is then excreted in the urine. The use of sodium 
phenylacetate/phenylbutyrate has never been investigated in the treatment of HE. This is 
because the degree of hyperglutaminemia seen in patients with urea‐cycle enzyme 
deficiencies and highly functional glutamine synthetase in the perivenous hepatocytes is 
rarely observed in patients with end‐stage liver disease or severe hepatocyte necrosis. 
Moreover, because the conjugation of phenylacetate is limited by the concentration of 
glutamine, limited availability of glutamine can lead to CoA sequestering, resulting in the 
inhibition of urea‐cycle synthesis and hyperammonemia. In addition, the sodium load 
associated with the treatment, which could lead to fluid retention and exacerbate ascites, 
has limited its use in patients with end‐stage liver disease. However, glycerol 
phenylbutyrate (HPN‐100; Hyperion Therapeutics), a liquid triglyceride that does not 
contain sodium and has a favorable palatability, has recently been shown to be as 
effective as sodium phenylacetate.
52
 It is currently being investigated as a treatment for 
HE in patients with end‐stage liver disease.  
Glutaminase inhibitors. The small intestine is an important source of ammonia 
generation, through the uptake and breakdown of glutamine by enterocytes. Phosphate‐
activated glutaminase is the main glutamine‐catabolizing enzyme in the small intestine, 
and current evidence indicates that 85% of intestinal ammonia production is the result of 
glutaminase activity. It has been demonstrated that the duodenal glutaminase activity in 
cirrhotic patients is nearly fourfold higher than that in healthy controls.
53
 Recently, a 
microsatellite (a sequence of repeated base pairs) discovered within the promoter region 
of the glutaminase gene was shown to be associated with the development of HE in 
patients with cirrhosis.
54
 Not only does this study identify a possible genetic marker for 
the development of HE, it also strongly suggests that glutaminase should be targeted as a 
This is the peer reviewed version of the following article: Rose C F. Ammonia-Lowering Strategies for the Treatment 
of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-09;92(3):321–331, which has been published in final form at 
10.1038/clpt.2012.112. This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Use of Self-Archived Versions. 
 
Rose C F. Ammonia-Lowering Strategies for the Treatment of Hepatic Encephalopathy. Clin Pharmacol Ther . 2012-
09;92(3):321–331 
potential ammonia‐lowering strategy. Currently, specific glutaminase inhibitors do exist, 
such as BPTES (bis‐2[5‐phenylacetamido‐1,2,4‐thiadiazol‐2‐yl]ethylsulfide), THDP17, 
and DON (6‐diazo‐5‐oxo‐L‐norleucine), but they have only been tested in vitro. The 
challenge is to avoid targeting and inhibiting all glutaminase activity, especially in in vivo 
systems, because glutaminase plays a vital role in cellular metabolism and organ 
function.  
Acarbose. Acarbose, an approved treatment for diabetes mellitus, is an inhibitor of α‐
glycosidase that primarily prevents the conversion of carbohydrates into 
monosaccharides. In addition, it has been demonstrated that acarbose can decrease 
colonic proteolytic flora and dietary nitrogenous substances. In a double‐blind, crossover, 
randomized study, 107 cirrhotic patients with OHE and type 2 diabetes mellitus received 
acarbose treatment and demonstrated a significant reduction in serum ammonia levels 
and attenuation of HE.
55
 Acarbose is well tolerated and is not associated with serious 
adverse effects. Additional studies are required to further evaluate the role and 
mechanism of action of acarbose in the treatment of HE.  
INCREASING THE AMOUNT OF AMMONIA REMOVAL 
Branched‐chain amino acids. Treatment with branched‐chain amino acids (BCAAs) has 
been shown to lower blood ammonia and improve the mental status of patients with end‐
stage liver disease.
56
 However, in 2004, a Cochrane review involving a meta‐analysis of 
11 randomized, controlled clinical trials concluded that BCAA supplementation does not 
affect morbidity or mortality in patients with end‐stage liver disease.57 Since then, a large 
multicenter, randomized study demonstrated that BCAA treatment reduces the risk of 
death and attenuates the progression of liver failure in patients with cirrhosis.
58
 The 
mechanisms underlying the ammonia lowering by BCAA remain elusive. It is known that 
BCAAs (valine, leucine, and isoleucine) are metabolically very active. In addition, 
through the enzyme branched‐chain aminotransferase, the amino group from the BCAA 
is utilized to form glutamate from α‐ketoglutarate and to detoxify ammonia through the 
production of glutamine via glutamine synthetase. Besides forming glutamate, BCAA 
metabolism, through branched‐chain aminotransferase, can generate branched‐chain 
ketoacids. These ketoacids are further metabolized into CoA compounds through 
branched‐chain α‐ketoacid dehydrogenase before being utilized in the tricarboxylic acid 
cycle for oxidative energy production (Figure 6). Therefore, in addition to lowering 
ammonia levels through biochemical action, BCAAs can indirectly increase ammonia 
removal by acting as anticatabolic agents. Leucine, in particular, is capable of stimulating 
protein synthesis in the liver and attenuating the degradation of muscle protein. The 
maintenance of muscle mass is critical in patients with liver dysfunction, because the 
muscle is an important ammonia‐removing organ, especially in the context of liver 
failure.
59
 BCAAs are believed to be beneficial for patients with cirrhosis because they 
function as a nutritional supplement, reducing protein catabolism, preventing muscle 
wasting, and arresting progression of liver failure. This action of BCAAs would be 
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expected to decrease ammonia production and improve clearance. However, a recent 
study showed that BCAA treatment in patients with cirrhosis resulted in an increase of 
blood ammonia levels.
60
 This study, using [
13
N] ammonia positron emission tomography, 
concluded that BCAA metabolism in the skeletal muscle leads to an increase in 
glutamine production (through glutamine synthetase) from BCAA‐derived ammonia 
rather than from blood‐derived ammonia, as seen from the finding that the amount of 
glutamine released from the muscles was six times greater than the ammonia uptake. In 
this case, the glutamate derived from the BCAA reacts with the cofactor NAD
+
 
(nicotinamide adenine dinucleotide) to form α‐ketoglutarate, and ammonia, through the 
enzyme glutamate dehydrogenase (Figure 6). This BCAA‐induced ammonia is then 
removed through the formation of glutamine, released into the blood, and metabolized by 
glutaminase in extramuscular organs such as the kidney and intestine,
7
 causing a release 
of ammonia. Although BCAA treatment is regarded as safe, noncompliance with long‐
term treatment has been reported—primarily due to its poor palatability and solubility, 
the latter necessitating consumption of large quantities of water. Overall, BCAA 
treatment can be potentially beneficial as an ammonia‐lowering strategy and as a 
treatment for HE, but to date its efficacy remains a matter of debate. A therapeutic dosing 
range of BCAA needs to be established for reliably lowering blood ammonia levels in 
cirrhotic patients with HE.  
 
Figure 6 Branched‐chain amino acids (BCAA) stimulating ammonia metabolic 
pathways. Valine, leucine, and isoleucine, along with α‐ketoglutarate, can be 
transaminated through the enzyme branched‐chain amino acid transaminase (BCAT) to 
branched‐chain ketoacids (BCKA) and glutamate. Ketoacids can be metabolized by 
branched‐chain α‐ketoacid dehydrogenase (BCKDH) to help fuel the tricarboxylic acid 
(TCA) cycle. Glutamate can either be used to stimulate glutamine synthetase (GS) and 
remove ammonia or be metabolized by glutamate dehydrogenase (GDH) to form α‐
ketoglutarate and ammonia. BCAA‐derived glutamine can also form ammonia afresh 
through phosphate‐activated glutaminase (PAG). 
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L‐ornithine–L‐aspartate. L‐ornithine–L‐aspartate (LOLA), both substrates of the urea 
cycle, were first tried as infusion treatments in patients suffering from end‐stage liver 
disease and HE, in an attempt to lower blood ammonia by stimulating ureagenesis in the 
residual hepatocytes (Figure 7a). This concept has been proven to work in ammonia‐
injected portacaval‐shunted rats, in which LOLA infusion prevented a rise in ammonia 
with a concomitant increase in urea production.
61
 In addition, LOLA has the 
demonstrated ability to stimulate glutamine synthesis, particularly in the skeletal 
muscle.
61,62
 L‐ornithine is a substrate for ornithine aminotransferase that gives rise to 
glutamate and glutamate semialdehyde, which can be further metabolized through 
glutamate semialdehyde dehydrogenase to form another molecule of glutamate. L‐
aspartate is also capable of generating a molecule of glutamate through aspartate‐α‐
ketoglutarate transaminase. Therefore, L‐ornithine and L‐aspartate taken together can 
produce three molecules of glutamate, which in turn can fuel glutamine synthesis activity 
and detoxify ammonia (Figure 7b). It should also be noted that glutamate can be 
metabolized by glutamine dehydrogenase to form α‐ketoglutarate and ammonia. Several 
clinical studies have demonstrated that LOLA (administered either orally or 
intravenously) lowers ammonia concentrations, provides symptomatic improvement in 
cirrhotic patients with HE,
63
 markedly improves health‐related quality of life, and is as 
effective as lactulose in the management of HE. In 2008, a Cochrane review, which 
included a meta‐analysis, reported that LOLA treatment led to the attenuation of OHE; it 
was, however, less beneficial in patients with MHE.
64
 In 2009, Acharya et al. concluded, 
following a randomized trial of 201 patients with acute liver failure, that treatment with 
LOLA did not improve ammonia reduction, attenuate encephalopathy, or increase 
survival.
65
 However, it is important to note that in this study, mortality in the placebo 
group was as low as 33% in comparison with an earlier study by the same group that 
reported 52% mortality in the placebo group.
66
 This reduction in mortality may be due to 
improvements in standard care, including prophylactic administration of antibiotics 
(piperacillin–tazobactam, fluconazole, and vancomycin). In addition, vancomycin has 
been shown to reduce ammonia levels in patients with cirrhosis.
29
 Therefore, it was 
conclusively shown that, in patients with acute liver failure, LOLA administration could 
not induce further reductions in ammonia to levels below those achieved by the standard 
care given to a placebo group, and that LOLA (administered at a dose of 30 g/day for 3 
days) was not a good adjuvant to the standard care. However, very good tolerability has 
been documented for LOLA treatment, with no major adverse effects. The results of 
many studies suggest that LOLA is an efficient and promising treatment for HE in 
patients with end‐stage liver disease. However, caution should be exercised in using 
LOLA to treat patients with acute liver failure. It appears that the duration and dosage of 
the LOLA treatment regimen are vital to its success and therefore need to be established. 
LOLA is currently not available for clinical use in North America.  
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Figure 7 Possible ammonia pathways induced by L‐ornithine L‐aspartate. (a) L‐ornithine 
L‐aspartate, a substrate and intermediate of the urea cycle, can lower ammonia by 
stimulating ureagenesis. (b) L‐ornithine and L‐aspartate can also be transaminated with 
α‐ketoglutarate to glutamate, through ornithine aminotransferase (OAT) and aspartate 
aminotransferase (AAT), respectively. Ornithine‐derived glutamate semialdehyde can be 
further metabolized to glutamate through glutamate semialdehyde dehydrogenase 
(GSDH). These three molecules of glutamate can be used to stimulate glutamine 
synthetase (GS), thus forming glutamine and removing ammonia. However, L‐ornithine 
L‐aspartate–derived glutamine can be metabolized through phosphate‐activated 
glutaminase (PAG), thereby regenerating ammonia. GDH, glutamate dehydrogenase. 
L‐carnitine. L‐carnitine, a metabolite produced by the degradation of the essential amino 
acid lysine, serves as a carrier for short‐chain fatty acids across the mitochondrial 
membrane. Treatment with L‐acetylcarnitine (the acetylated form of L‐carnitine, known 
to increase its bioavailability) significantly reduced serum ammonia levels and improved 
mental status as compared with placebo in 150 cirrhotic patients with mild to moderate 
HE.
67
 However, despite reductions in blood ammonia levels, an overall worsening per the 
Glasgow Coma Scale was noted in critically ill cirrhotic patients with hepatic coma who 
had received L‐carnitine.68 L‐acetylcarnitine, given as pretreatment to portacaval‐shunted 
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rats, was shown to prevent ammonia‐induced encephalopathy; however, it did not 
provide a significant protection against an increase in blood ammonia levels after rectal 
administration of ammonia in subjects with cirrhosis.
69
 
COMBINATION OF AMMONIA‐LOWERING AGENTS 
Targeting a single strategy. Recently, numerous studies have been published describing 
various combinations of ammonia‐lowering agents as treatment for HE in patients with 
cirrhosis. Some were intentionally designed to investigate the benefit of simultaneously 
administering two ammonia‐removing agents, such as the study by Sharma et al., which 
investigated the beneficial effect of lactulose vs. probiotics vs. lactulose + probiotics. All 
three treatments were equally effective in lowering blood ammonia and in treating 
MHE.
70
 Other studies generated results of combination strategies as part of comparisons 
with lactulose, the standard care regimen in these studies. Recently, lactulose + rifaximin 
has been demonstrated to be more beneficial in preventing a recurrence of HE as 
compared to lactulose alone.
34
 Each of the above‐mentioned studies describes the effect 
of combining two treatments, each targeting the gut, modulating the microflora, and, in 
effect, lowering the production of ammonia. In another study, two agents with ammonia‐
removing properties (L‐acetylcarnitine + BCAA) were combined. The results of this 
study demonstrated that L‐acetylcarnitine + BCAA causes greater reduction in blood 
ammonia and is more beneficial in attenuating HE as compared to BCAA treatment 
alone.
71
 Sodium phenylacetate and sodium benzoate were also evaluated as a 
combination (Ammonul; Hyperion Therapeutics), and this regimen was approved for the 
treatment of hyperammonemia associated with urea‐cycle disorders.72 The strategy 
behind combining sodium phenylacetate and sodium benzoate is that each of these agents 
chelates different ammoniagenic substrates. With sodium phenylacetate conjugating with 
glutamine, and sodium benzoate conjugating with glycine, two substrates for potential 
ammoniagenesis are thus removed. In the context of HE, this combination has previously 
been tested in a small study that suggested its possible benefit.
73
 It was to be tested in a 
clinical trial to investigate the beneficial effects of sodium phenylacetate and sodium 
benzoate (Ammonul; Hyperion Therapeutics) in cirrhotic patients with severe HE. 
However, for undisclosed reasons, the study was withdrawn prior to enrollment 
commenced (http://www.clinicaltrials.gov).  
Overall, the idea of combining treatments targeting different ammonia‐
producing/lowering systems is a valuable concept. However, selecting two agents that 
both inhibit ammonia production or increase ammonia removal in the same organs may 
be an excessive and redundant strategy. 
Synergy of two strategies: L‐ornithine phenylacetate. L‐ornithine phenylacetate (OCR‐
002; Ocera Therapeutics) represents a new combination treatment strategy by which, for 
the first time, an agent is administered in order to activate ammonia removal in 
combination with another agent that stimulates a reduction in ammonia production. The 
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idea of this synergistic treatment, developed by Rajiv Jalan in the United Kingdom,
74
 is 
based on the fact that L‐ornithine (the active component of LOLA)75 generates glutamate 
(through ornithine aminotransferase in muscle), thereby stimulating glutamine synthesis 
and reducing blood ammonia. This, in turn, leads to an increase in ornithine‐derived 
glutamine. To prevent glutamine from being metabolized by glutaminase and forming 
ammonia again, phenylacetate is administered to conjugate with the ornithine‐derived 
glutamine to form phenylacetylglutamine. Consequently, given that glutaminase is 
incapable of metabolizing phenylacetylglutamine, an ammonia rebound is prevented and 
phenylacetylglutamine is excreted by the kidneys (Figure 8). The proof of concept for the 
mechanism of L‐ornithine phenylacetate was first tested in liver‐devascularized pigs to 
negate the possibility of L‐ornithine stimulating ureagenesis.10 In that study, L‐ornithine 
phenylacetate treatment attenuated increases in blood and brain ammonia, brain edema, 
and intracranial hypertension—results that were not achieved with either L‐ornithine or 
phenylacetate treatment alone. L‐ornithine phenylacetate has also been shown to be 
effective in lowering blood ammonia in cirrhotic rats and portacaval‐shunted rats with 
simulated gastrointestinal bleed.
9,14
 To date, animal studies have demonstrated the 
efficacy of L‐ornithine phenylacetate as an ammonia‐lowering strategy. Currently, two 
phase II clinical trials of the safety and tolerability of L‐ornithine phenylacetate treatment 
are under way in Spain and the United States (http://www.clinicaltrials.gov): (i) in 
patients with acute liver failure due to acetaminophen overdose and (ii) in patients with 
cirrhosis and upper gastrointestinal bleeding. This promising synergistic treatment, which 
combines two agents that do not target the gut, is very novel. As a therapeutic strategy, it 
would allow patients with cirrhosis to be properly nourished (stable protein diet) and 
would inhibit the development of hyperammonemia by increasing ammonia elimination.  
 
Figure 8 The synergistic mechanism of L‐ornithine phenylacetate. L‐ornithine (with α‐
ketoglutarate) can produce two molecules of glutamate through glutamate semialdehyde 
dehydrogenase (GSDH) and ornithine aminotransferase (OAT) that can stimulate 
glutamine synthetase (GS), thereby removing ammonia and forming glutamine. To 
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prevent ornithine‐derived glutamine from being metabolized by phosphate‐activated 
glutaminase (PAG), phenylacetate conjugates with glutamine to form 
phenylacetylglutamine, which is then excreted in the urine, and thus regeneration of 
ammonia is prevented. GDH, glutamate dehydrogenase. 
SUMMARY 
HE, a devastating neuropsychiatric syndrome, is a major complication of liver failure. 
Because ammonia plays such a major role in the pathogenesis of HE, ammonia‐lowering 
strategies remain a focus for HE treatments. Historically, ammonia‐lowering strategies 
have concentrated on inhibiting the source of ammonia production in the gut; currently, 
lactulose and rifaximin are the treatments of choice for HE. Other agents that inhibit 
ammonia production include probiotics, glutaminase inhibitors, and AST‐120. However, 
they all need to be evaluated in high‐quality clinical trials. An alternative ammonia‐
lowering strategy involves increasing ammonia removal. This focuses primarily on 
stimulating glutamine synthetase in the large mass capacity of skeletal muscle. BCAAs, 
LOLA, and L‐ornithine phenylacetate have all been shown to be capable, through 
transamination, of generating glutamate, which stimulates glutaminase synthetase, 
producing glutamate and eliminating ammonia. However, under certain conditions, the α‐
ketoglutarate generated can form ammonia through glutamate dehydrogenase; also, 
glutamine, the ammonia‐removing product, can itself be metabolized by glutaminase to 
produce ammonia afresh. Given that glutaminase has been described as an important 
enzyme associated with the risk of developing HE, glutamine would seem to be a 
secondary product that should be targeted for elimination. Paradoxically, however, the 
production of glutamine is required for the removal of ammonia. In this situation, the use 
of L‐ornithine phenylacetate is an excellent strategy, not only to stimulate glutamine 
synthesis (ammonia removal) but also to prevent a glutamine‐induced ammonia rebound.  
Furthermore, given that malnourishment is a major concern in cirrhotic patients, targeting 
the gut to lower ammonia, thereby possibly altering intestinal absorption, may exacerbate 
malnutrition. Therefore, exploitation of ammonia‐removing pathways in other organs is a 
potential treatment strategy; for instance, the large mass capacity of skeletal muscle 
renders it an attractive therapeutic target. However, sarcopenia is commonly observed in 
patients with cirrhosis; considered independently, it may be a result of malnutrition, 
which, as noted above, has a detrimental effect on outcome in terms of complications, 
survival after liver transplantation, and overall liver‐related mortality. Therefore, to 
benefit from using the muscle as a therapeutic target, the detection of malnutrition is of 
pivotal importance. Proper nutrition that prevents loss of muscle mass in cirrhotic 
patients can independently lead to an increase in ammonia‐removal capacity, as well as to 
a much better response to BCAA, LOLA, and L‐ornithine phenylacetate in stimulating 
glutamine synthesis, with L‐ornithine phenylacetate being the most beneficial in 
preventing glutaminase‐induced ammonia rebound.   
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